Exscientia – the world-leading Artificial Intelligence (AI)-driven drug discovery company - is pleased to announce a drug discovery collaboration with Roche.
Exscientia will apply its cutting-edge, Centaur Chemist™, AI drug discovery platform to design pre-clinical drug candidates for Roche. Roche has the exclusive rights to develop and market the drug candidates resulting from the collaboration.
Exscientia receives upfront and research funding as well as pre-clinical, development and commercial milestone payments. Together, the combined financial reward is worth up to CHF 67 million to Exscientia, plus tiered royalties on the annual net sales of any products resulting from the collaboration. No further financial details are disclosed.
Andrew Hopkins, CEO of Exscientia, said: